Bioequivalence Study to Compare Chenodeoxycholic Acid Capsules (250mg Chenodeoxycholic Acid) Versus Chenodeoxycholic Acid Leadiant 250 mg Hard Capsules (250mg Chenodeoxycholic Acid)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 12, 2022

Primary Completion Date

July 18, 2022

Study Completion Date

August 15, 2022

Conditions

Cerebrotendinous Xanthomatoses

Interventions

DRUG

Chenodeoxycholic acid

Two capsules were administered orally

DRUG

Chenodeoxycholic acid leadiant

Two capsules were administered orally

Trial Locations (1)

ACDIMA Biocenter, Amman

All Listed Sponsors

lead

Humanis Saglık Anonim Sirketi

INDUSTRY